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Abstract
Background The global phase 3 studies of golimumab
[PURSUIT-SC and PURSUIT-maintenance (M)], an anti-
tumor necrosis factor-a (anti-TNFa) antibody, have
demonstrated clinical efficacy and safety as induction and
maintenance therapies in patients with moderate to
severely active ulcerative colitis (UC). This study aimed to
evaluate the efficacy and safety of golimumab as mainte-
nance therapy in the Japanese population.
Methods In this phase 3, double-blind (DB), placebo-
controlled, parallel group, randomized withdrawal study,
144 Japanese patients with moderately to severely active
UC received golimumab doses of 200 mg (at week 0) and
100 mg (at week 2) subcutaneously during the 6-week
open-label induction phase. Patients who responded to
golimumab induction therapy entered the DB maintenance
(M) phase and were randomized (1:1) to receive 100 mg of
golimumab subcutaneous injection (SC) or placebo every
4 weeks for 52 weeks. The primary endpoint was clinical
response through M-week 54; secondary endpoints inclu-
ded clinical remission and mucosal healing at M-week 30
and 54.
Results Among induction responders, more patients on
golimumab treatment (56.3%) maintained clinical response
through M-week 54 versus the placebo group (19.4%). At
both M-week 30 and 54, 50% golimumab-treated patients
achieved clinical remission versus the placebo group
(6.5%) and a higher proportion of patients on golimumab
(59.4%) experienced mucosal healing than the placebo
group (16.1%). Incidence of treatment-emergent adverse
events was 96.9% in the golimumab group and 71% in the
placebo group. Overall, the efficacy and safety results in
this study were comparable with those observed in global
studies.
Conclusions Golimumab SC treatment maintained clinical
efficacy through week 54 among induction responders, and
no new safety signals were observed in the patients with
moderate to severely active UC.
Clinical Trial Registration: The study is registered at
ClinicalTrials.gov NCT01863771.
Keywords Anti-TNFa antibody  Golimumab  Japanese
patients  PURSUIT  Ulcerative colitis  Maintenance
therapy
Introduction
Ulcerative colitis (UC), a chronic inflammatory bowel
disease (IBD) confined to the colon, is characterized by
diarrhea, rectal bleeding, rectal urgency and tenesmus [1].
The prevalence of UC is high in western countries; in USA,
the prevalence ranges from 37 to 246 per 100,000 persons
[2, 3]. In Japan, the age-standardized prevalence of UC in
2005 was 63.6 per 100,000 persons and it is rapidly
increasing with time, although at a comparatively lower
rate than the western countries. Growing incidence and
emergence of UC in formerly low-risk populations like
Japan highlight the effects of the environment and the
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growing western influence on dietary habits [4, 5]. In
addition to westernization, familial traits, genetics and
smoking habits also contribute to the development and
progression of UC [5].
The conventional therapies used for the management of
moderately to severely active UC include 5-aminosalicy-
late (5-ASA) compounds, corticosteroids, immunomodu-
lators such as 6-mercaptopurine (6-MP), azathioprine
(AZA) and cyclosporine. However, many patients fail to
achieve adequate response and tolerate conventional ther-
apies [6]. As tumor necrosis factor (TNF)-a, a proinflam-
matory mediator, plays an integral role in the pathogenesis
of UC, treatment with TNF-a antagonist such as infliximab
has proven to be effective in moderate to severe UC [7, 8].
Golimumab, a fully human monoclonal anti-TNFa
antibody, was approved in the USA and the European
Union in 2013 for induction and maintenance treatment of
moderately to severely active UC. The approval was based
on two phase 3 clinical studies (Program of Ulcerative
Colitis Research Studies Utilizing an Investigational
Treatment [PURSUIT]-SC, a 6-week induction study [9]
and the PURSUIT-Maintenance [PURSUIT-M], a 54-week
maintenance study [10]), which evaluated the efficacy and
safety of golimumab subcutaneous injection (SC) in mod-
erately to severely active UC patients who were refractory
or intolerant to conventional UC therapies. Both the
PURSUIT-SC and PURSUIT-M studies also enrolled
Japanese patients; however, the small sample size of
Japanese patients limits the generalizability of the results in
these patients. Hence, the present study was conducted to
evaluate the efficacy and safety of golimumab via SC as
maintenance therapy in Japanese patients with moderately
to severely active UC and to confirm the similarities of
golimumab efficacy and safety between this study and
those observed in the PURSUIT-M study.
Methods
Patients
Japanese patients (both men and women aged C18 years)
with moderately to severely active UC, as defined by a
Mayo score of 6–12 with a local endoscopic subscore C2 at
baseline of induction phase were eligible if they had an
inadequate response to or had failed to tolerate one or more
conventional therapies [oral 5-aminosalicylates, oral cor-
ticosteroids, azathioprine (AZAs) and/or mercaptopurine]
or had demonstrated corticosteroid dependence. All
patients in this study were TNF a therapy-naı¨ve. In addi-
tion, eligible patients were to have a stool culture negative
for enteric pathogens and patients aged C45 years were to
have undergone a colonoscopy to assess the presence of
adenomatous polyps (within 5 years prior to first admin-
istration of study agent) and adenomatous polyps were to
be removed prior to the first administration of any study
agent. Patients with no history of latent or active tubercu-
losis (TB) prior to screening were included. In the
screening phase, infections were assessed by an investi-
gator. Two months prior to the first administration of
golimumab, patients were screened for TB using the
interferon-gamma release assays (IGRAs): QuantiFERON-
TB Gold Testing and T-SPOT.TB test, chest radiographic
and lung computed tomography (CT). Patients were also
screened for hepatitis B virus (HBV) infections using the
HBsAg (HBV surface antigen), anti-HBs (HBV surface
antibody) and anti-HBc total (HBV core antibody total)
assays.
Patients with a history of severe and extensive colitis
who required colectomy; or who had colits limited to
20 cm of the colon or rectum, symptomatic colonic or
small bowel obstruction, colonic mucosal dysplasia,
extensive colonic resection or any other intra-abdominal
surgery within a specified interval prior to screening; or
patients having presence of fistula or adenomatous colonic
polyps (not removed) were not included in this study.
The institutional review board at the study site approved
the protocol and the study was conducted in accordance
with the ethical principles that have their origin in the
Declaration of Helsinki, consistent with good clinical
practices and applicable regulatory requirements. All
enrolled patients provided written consent for their partic-
ipation in the study.
Study design
This was a phase 3, double-blind, placebo-controlled,
2-arm parallel group, randomized withdrawal study con-
ducted at 49 centers in Japan between February 2013 to
January 2016. The study consisted of a 6-week open-label
induction phase (I) and a 54-week double blind (DB)-
maintenance phase (M; Fig. 1). In the open-label induction
period (I-week 0 to I-week 6), all patients received 200 mg
of golimumab via SC at I-week 0 and 100 mg at I-week 2.
At I-week 6 (i.e. M-week 0), patients who achieved clinical
response (CR) entered the DB-maintenance phase as the
primary population and were randomized (1:1) to receive
either 100 mg of golimumab or an equivalent placebo
every 4 weeks through M-week 52. Treatment allocation
was based on a computer-generated randomization sched-
ule that used permuted block randomization with stratifi-
cation factors as clinical remission and corticosteroid use at
M-week 0 (yes or no). For patients with a confirmed loss of
CR, the following dose adjustments were permitted once
during the study: patients on placebo received 100 mg of
golimumab every 4 weeks and patients on golimumab
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treatment continued receiving the same dose every
4 weeks. The study was registered at ClinicalTrials.gov
NCT01863771.
Nonresponders to golimumab induction treatment were
included in the open-arm [open-label (OL)-maintenance
phase] to receive 100 of golimumab via SC at M-week 0
and M-week 4. However, at M-week, eight patients who
did not show improvements in Mayo score from I-week 0
were discontinued from the study. All patients had a fol-
low-up at 16 weeks after the last golimumab administra-
tion for safety assessments.
Patients on corticosteroid therapy at I-week 0 were
continued on the therapy through the induction phase. For
patients in CR to golimumab in the induction phase, dose
tapering for corticosteroids should have been performed
from M-week 0. The recommended rate of corticosteroid
tapering was not more than 5 mg/week for patients on a
corticosteroid dose[20 mg/day and not more than 2.5 mg/
week for patients on a corticosteroid dose B20 mg/day.
Study evaluations and endpoints
Primary efficacy endpoint
The primary efficacy endpoint was defined as maintenance
of CR through the end of the DB-maintenance phase (M-
week 54) in golimumab responders (induction responders).
It was assessed using the Mayo score, a composite endo-
scopic clinical score calculated as a sum of four subscores:
stool frequency, rectal bleeding, endoscopy findings and
physician’s global assessment. Mayo overall score values
range from 0 to 12 with higher scores indicative of severe
disease condition [11].
CR was measured as a decrease in the Mayo score by
C30% and C3 points from I-week 0, along with a fall in the
rectal bleeding subscore of C1 or a rectal bleeding sub-
score of 0 or 1. Mayo scores were calculated at I-week 0,
M-week 0, M-week 30 and M-week 54. In addition,
patients experiencing an increase in disease activity (i.e.,
clinical flare defined as an increase in the partial Mayo
score of at least two points from baseline [M-week 0] with
an absolute partial Mayo score C4 or an absolute partial
Mayo score C7) at any time during the study were also
assessed for loss of CR using Mayo scores. Partial Mayo
scores defined as Mayo scores without endoscopic assess-
ments were calculated at all study time points.
Secondary endpoints
Clinical remission (defined as a Mayo score of B2 points,
with no individual subscore [1) and mucosal healing
(measured using a Mayo endoscopic subscore of 0 or 1) at
both M-week 30 and M-week 54. Other efficacy endpoints
were: proportion of patients who maintained clinical
remission at both M-week 30 and M-week 54 among
patients induced into clinical remission with SC goli-
mumab; proportion of patients achieving clinical remission
and eliminating corticosteroid use at M-week 54 among
Fig. 1 Study design and patient disposition. E Primary efficacy
evaluation, DB double-blind, I-week induction week, M-week main-
tenance week, OL open-label, SC subcutaneous; a every 4 weeks
through M-week 52; b patients who responded to golimumab 100 mg
at M-week 8 continued to receive golimumab 100 mg every 4 weeks
through M-Week 52 at the same dose
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patients receiving concomitant corticosteroids at M-week
0; change in Mayo scores and partial Mayo scores from
baselines (I-week 0 and M-week 0); proportion of patients
who reported mucosal healing at various time points and
change from baseline in corticosteroid use at M-week 30
and M-week 54. Health-related quality of life was assessed
using a patient-reported IBD questionnaire (IBDQ), a
32-item self-reported questionnaire that evaluated bowel
symptoms, systemic symptoms, social function and emo-
tional functions [12]. Improvements in the IBDQ was
assessed in patients who had[20-point improvement in the
IBDQ score [13] at M-week 0 from I-week 0. The pro-
portion of patients with sustained improvement in their
IBDQ score of[20 points at M-week 30 and M-week 54
was also assessed.
Immunogenicity and biomarkers
Immunogenicity was measured by antibody detection and
characterization from I-week 0 through the follow-up visit
at week 68. Blood samples were collected prior to study
drug administration on I-week 0, I-week 6, M-week 28,
M-week 30, M-week 52, M-week 54 and M-week 68 (for a
final safety evaluation). Assessments for biomarkers such
as C-reactive protein (CRP), fecal lactoferrin and calpro-
tectin were also performed.
Safety evaluations
Safety and tolerability were assessed through the induction
and maintenance phases and involved monitoring treat-
ment-emergent adverse events (TEAEs), laboratory tests
(hematology, serum chemistry), ECG, and measurement of
vital signs, physical evaluations, injection site evaluations,
TB evaluation and infections.
Statistical analysis
Sample size
The number of patients enrolled in this study was dependent
on the target population who were randomized into the DB-
maintenance phase. Based on the results of the global PUR-
SUIT-M study [10] (with the Japanese subpopulation), the
assumed CR would be 30% during the induction phase.
Therefore, to ensure a total patient population of 60 during the
DB-maintenance phase, a total of 200 patients were required
to be enrolled assuming a CR of 30% in the induction phase.
Primary efficacy analysis
The primary hypothesis of this study was based on achieve-
ment of difference in efficacy between golimumab
maintenance treatment (100 mg SC, every 4 weeks, for
52 weeks) and placebo groups as per predefined criterion:
CR100–CRP C8.5%, where CR100 and CRP were the point
estimates of the proportion of patients in CR through M-week
54 (i.e. M-week 0, 30, 54) in the golimumab and placebo
groups. A lower limit of 95% confidence interval (CI) was
used to establish the efficacy criterion for the primary endpoint
in the current study population consisting of Japanese adult
patients, which was established based on the data from CR
through M-week 54 between the 100 mg of golimumab group
and the placebo group in the global PURSUIT–M study [10].
Analysis sets
Efficacy All patients who received the induction treatment
were included in the efficacy full analysis set for the
induction phase (FAS-I). The primary analysis set for the
DB-maintenance phase (FAS-DB) included the target
population, i.e., all patients who were randomized at
M-week 0, whereas nonrandomized patients who entered
the OL-maintenance phase were included in the open-label
maintenance phase full analysis set (FAS-OL). All treat-
ment group comparisons were performed at a two-sided a
level of 0.05 and the CI was also estimated.
The proportion of patients who maintained CR, clinical
remission at M-week 30 and M-week 54 with mucosal
healing at M-week 30 and M-week 54 and achieved cor-
ticosteroid-free clinical remission at week 54 in the FAS-
DB were calculated per treatment group. Actual values and
change from baseline in the Mayo and partial Mayo scores
over time in patients in the FAS-I, FAS-DB and FAS-OL
analysis sets were summarized by treatment group.
Immunogenicity and biomarker assessments were based
on the immune response (IR) analysis set and included
patients who received at least one administration of goli-
mumab and had at least one observed IR value after
administration. Changes from baseline values (I-week 0
and M-week 0) in CRP concentrations, fecal lactoferrin and
calprotectin concentrations (log-transformed) over time
were compared between golimumab and placebo at I-week
6 and M-week 16, 30 and 54.
Patient-reported outcomes: patients with [20-point
improvement in the IBDQ score at M-week 0 from
induction baseline and the proportion of patients with
sustained improvement in the IBDQ score from baseline (I-
week 0) of[20 points at M-week 30 and M-week 54 were
summarized by treatment group.
Safety All patients who received at least one adminis-
tration of induction treatment were included in the safety
analysis for the induction phase (SF-I). In the DB-main-
tenance phase, the target population was included in the
DB-maintenance phase safety set (SF-DB), while nonran-
domized patients who entered the OL-maintenance phase
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were included in the OL-safety set (SF-OL). Safety eval-
uations were summarized descriptively.
Results
Demographic and baseline characteristics
A total of 144/186 screened patients (77.4%) initiated goli-
mumab treatment in the induction phase. Of the 144 patients,
123 patients (85.4%) completed the induction phase at
I-week 6 and entered the maintenance phases. A total of 63
(43.8%) patients achieved CR to golimumab treatment in the
induction phase and were randomized to receive 100 mg of
golimumab (32 patients) or to be placed in the placebo group
(31 patients) in the DB-maintenance phase as the primary
population (Table 1). Furthermore, 60/123 patients who
completed the induction phase, but were nonresponders to
induction dosing at I-week 6/M-week 0, entered the OL-
maintenance phase without randomization. The proportion
of patients who discontinued study/terminated the study
participation in the maintenance phase was greater in the
nonrandomized patients [71.7% (43/60)] than the random-
ized patients [27.0% (17/63)]. Of the 63 randomized patients,
34 patients were considered treatment failures (goli-
mumab = 10, placebo = 24) and 27 patients (goli-
mumab = 8, placebo = 19) underwent dose adjustments.
All 19 patients on placebo earlier underwent dose adjust-
ments to receive 100 mg of golimumab.
For patients enrolled in the induction phase (n = 144),
the median duration of UC was 5.08 years, the median
Mayo score was 8.0 and extensive disease was observed in
38.2% of patients. Concomitant medications at baseline
were 5-aminosalicylates (89%), corticosteroids (29%) and
immunosuppressive AZA/6-mercaptopurine (46%). No
patients were on budesonide therapy or methotrexate
Table 1 Demographic and baseline characteristics at I-week 0 (full analysis set for the induction, DB-maintenance and OL-maintenance phases)
Induction phase DB-Maintenance phase OL-Maintenance phase
Golimumab SC 200 mg Golimumab SC 100 mg Placebo* 100 mg Golimumab SC 100 mg
N 144 32 31 60
Sex, male, n (%) 98 (68%) 19 (59%) 19 (61%) 42 (70%)
Age (years) 42.40 (14.74) 39.30 (12.00) 42.90 (14.41) 42.10 (16.16)
Weight (kg) 61.51 (11.18) 64.59 (14.73) 59.48 (9.73) 60.97 (9.74)
Height (cm) 165.63 (7.50) 163.77 (7.05) 163.49 (6.21) 167.09 (7.77)
BMI (kg/m2) 22.38 (3.69) 24.07 (5.44) 22.22 (3.24) 21.78 (2.77)
Disease durationa, years 5.08 (0.1;27.4) 5.35 (0.5;24.7) 5.74 (0.3;21.6) 4.57 (0.3;27.4)
Extent of disease, n (%)
Limited to left side of colon 89 (62%) 20 (63%) 19 (61%) 37 (62%)
Extensive 55 (38%) 12 (38%) 12 (39%) 23 (38%)
Mayo scorea (0–12) 8.0 (6;12) 8.0 (6;11) 8.0 (6;12) 8.0 (6;11)
Severity of UC disease, n (%)
Moderate 141 (98%) 31 (97%) 30 (97%) 59 (98%)
CRP (mg/L) 4.90 (10.95) 5.31 (14.79) 4.06 (7.74) 4.68 (11.06)
Any UC medication, n (%) 141 (98%) 32 (100%) 30 (97%) 59 (98%)
Corticosteroid# 42 (29%) 9 (28%) 9 (29%) 19 (32%)
C20 mg/day P.Eq 12 (8%) 4 (13%) 5 (16%) 3 (5%)
\20 mg/day P.Eq 30 (21%) 5 (16%) 4 (13%) 16 (27%)
Budesonide 0 0 0 0
Immunomodulatory drugs
6-MP/AZA 64 (44%) 16 (50%) 13 (42%) 28 (47%)
Methotrexate 0 0 0 0
Aminosalicylates 128 (89%) 29 (91%) 27 (87%) 55 (92%)
All values expressed as mean (SD) unless otherwise mentioned
6-MP 6-mercaptopurine, AZA azathioprine, BMI body mass index, CRP C-reactive protein, DB double-blind, OL open-label, SC subcutaneous
injection, SD standard deviation, UC ulcerative colitis
a Values expressed in median (range)




therapy concomitantly. Baseline demographics were gen-
erally similar among the treatment groups (Table 1).
Efficacy
Induction phase
Of the 144 patients treated with golimumab, 63 patients
(43.8%) achieved CR, 27 patients (18.8%) achieved clini-
cal remission and 53 patients (36.8%) achieved mucosal
healing at I-week 6. A reduction in the Mayo score was
observed from baseline at the end of the induction phase (I-
week 6), with a median Mayo score of 6.5 (0 to 11) and a
median reduction of -2.0 (-9 to 3). Consistently, a
reduction in the partial Mayo score was also observed from
baseline with a median partial Mayo score of 4.0 (0 to 9)
and median reduction of -1.0 (-8 to 3).
Maintenance phases
Primary endpoint
More patients on golimumab treatment [56.3% (18/32)]
maintained CR through M-week 54 than in the placebo
group [19.4% (6/31)] and the difference in the proportion
of patients between the two treatment groups was 36.9%,
(95% CI 14.8; 59.0) which was above the prespecified
criterion of C8.5% (Fig. 2).
Other end-points in maintenance phases
A higher proportion of responders in the golimumab group
[50.0% (16/32)] achieved clinical remission at both
M-week 30 and M-week 54 as compared with patients in
the placebo group [6.5% (2/31)] and the difference in the
proportion of patients between the two treatment groups
was 43.6% [95% CI: 24.2; 62.9, (Fig. 3a)]. Of the 63
patients who were randomized in the DB-maintenance
phase, 14/32 golimumab patients and 13/31 placebo
patients were in clinical remission at the baseline visit of
the DB-maintenance phase M-week 0. Among these
patients, 9/14 (64.3%) golimumab patients and 2/13
(15.4%) placebo patients were in clinical remission at both
M-week 30 and M-week 54. More patients on golimumab
treatment [59.4% (19/32)] experienced mucosal healing
than patients on placebo [16.1% (5/31)] at both M-week 30
and M-week 54 and difference in the proportion of patients
between the two treatment groups was 43.3% [95% CI
21.9; 64.6 (Fig. 3b)].
The Mayo scores remained stable at M-week 30 and
M-week 54 for patients on golimumab treatment but a
median increase of 4.0 (-2 to 8) and 5.0 (-3 to 8) at
M-week 30 and M-week 54, respectively, was observed for
patients receiving placebo treatment. The partial Mayo
score decreased from 6 at I-Week 0 to 2 at I-week 6/M-
week 0 in the induction phase; a further decrease to 1 at
M-week 8 was observed and was maintained at 1 almost
through M-week 54 in the golimumab treatment group
(Fig. 3c). Consistent with the Mayo score, the partial Mayo
score also remained stable between baseline and M-week
30 and M-week 54 in the golimumab 100 mg group and a
median increase of 3.0 (-2 to 6) was observed at both
M-week 30 and M-week 54 from baseline in the placebo
group (Table 2).
In the OL-maintenance phase, the median Mayo scores
remained stable at M-week 30 [7.0 (0 to 10)] and M-week
54 [7.0 (0 to 11)] in the nonrandomized patients. Minimal
decrease in the median mayo score from baseline was
observed at M-week 8 with a median decrease of -1.0 (-6
to 3). Consistent with the Mayo score, change in partial
Mayo scores for the nonrandomized patients was also
minimal. A median decrease in partial Mayo scores [-1.0
(–4 to 3)] was observed at M-week 8 which remained
stable through M-week 54. Of the 60 nonrandomized
patients, 13 (21.7%) patients achieved mucosal healing at
M-Week 8 and 9/60 (15.0%) patients achieved mucosal
healing at both M-week 30 and M-week 54.
Corticosteroid use during the DB-maintenance
phase
Of the 63 randomized patients, 18 patients (each treatment
arm = 9), received corticosteroid therapy at baseline
M-week 0. Although the median average daily corticos-
teroid dose was similar in the two treatment groups, at
M-week 54, the number of patients in clinical remission
Fig. 2 Proportion of patients with clinical response through M-week




and not receiving concomitant corticosteroids was higher
in the golimumab treatment [55.6% (5/9)] as compared
with placebo treatment [11.1% (1/9)]. A greater reduction
from baseline in the mean daily corticosteroid dose was
observed in the golimumab group (M-week 30 = reduction
of 7.19 mg/kg P.Eq; M-week 54 = 6.50 mg/kg P.Eq) than
in the placebo group (M-week 30 = reduction of 6.67 mg/
kg P.Eq; M-week 54 = 3.33 mg/kg P.Eq).
Biomarkers and immunogenicity
The median CRP concentration at I-week 0 was 1.585 mg/
L for all patients in the induction phase. At I-week 6, the
median CRP concentration decreased by 0.190 mg/L from
baseline. At M-week 0, the median CRP concentrations
were comparable across the treatment groups and had
decreased from I-week 0 in both groups; however, the
median CRP concentrations in the golimumab 100 mg
group were lower than that in the placebo group at M-week
16 (0.075 mg/L vs. 0.240 mg/L), M-week 30 (0.080 vs.
0.250 mg/L) and M-week 54 (0.035 vs. 0.250 mg/L).
The median fecal lactoferrin concentration at I-week 0 was
1.88 for all patients in the induction phase. At I-week 6, the
median fecal lactoferrin concentration decreased by 0.30 from
baseline. The median fecal lactoferrin concentrations at
M-week 0 were higher in the golimumab 100 mg group (1.20)
than in the placebo group (0.78). From M-week 0, the change
in median fecal lactoferrin concentrations remained stable in
both groups: golimumab 100 mg group vs. placebo group at
M-week 30 (0 vs. 0.79) and M-week 54 (-0.04 vs. 0.76).
The median calprotectin concentration at I-week 0 was 2.70
for all patients in the induction phase. At I-week 6, the median
fecal calprotectin concentration decreased by 0.19 from base-
line. At M-week 30 and M-week 54, the change from baseline
in the median fecal calprotectin concentrations remained
stable from M-week 0 in the golimumab 100 mg group
whereas the concentrations increased in the placebo group
(Table 2).
Of all the 144 golimumab-treated patients in the induction
phase, no patient was positive for antibodies. During the DB-
maintenance phase, 4/63 were positive for antibodies to
golimumab (4/31 patients from placebo group). Among the
nonrandomized patients receiving golimumab treatment in
the OL-maintenance phase, 1/60 patient was positive for
antibodies. All five samples showed neutralizing activity
against golimumab.
Fig. 3 a Proportion of patients with clinical remission at both
M-week 30 and M-week 54; full analysis set for the DB-maintenance
phase. b Proportion of patients with mucosal healing at both M-week
30 and M-week 54; full analysis set for the DB-maintenance phase.
c Change of partial Mayo score overtime; full analysis set for the DB-
maintenance phase. CI confidence interval, DB double-blind, I-week




At the end of the induction phase, the median decrease in
the IBDQ scores at I-week 6 from I-week 0 was 11.0. A
higher proportion of patients on golimumab treatment
(55.0%, 11/20 patients) had[20-point improvement in the
IBDQ score at M-week 0 from I-week 0 as compared to
placebo (22.2%, 6/27) and was maintained through
M-Week 54. During the DB-maintenance phase, at
M-week 30 and M-week 54, the median change in all
IBDQ dimension scores from M-week 0 was lower in the
golimumab 100 mg group than in the placebo group, sug-
gesting a maintained improvement in their IBDQ dimen-
sion scores achieved during induction. In the OL-
maintenance phase, 10 patients had [20-point improve-
ment in the IBDQ score at M-week 0 from I-week 0. Of
these, 20% (2/10) of patients maintained [20-point
improvement in the IBDQ score through M-week 54.
Safety and tolerability
Induction phase
Of the 144 patients enrolled in the induction phase, 65
patients (45.1%) reported C1 TEAE, with nasopharyngitis
(17/144; 11.8%) and worsening of UC (9/144; 6.3%) being
the most frequent. A total of 5 patients (3.5%) reported
serious TEAEs [UC = (4/144; 2.5%) and cytomegalovirus
colitis = (1/144; 0.7%)]. A total of 10 patients discontin-
ued the study due to TEAEs, with the most common TEAE
being worsening of UC (8/144; 5.6%). Decreased absolute
lymphocyte count was observed in 12/144 (8.3%) patients
Table 2 Mayo score, partial Mayo score, mucosal healing and corticosteroid use at M-week 30 and M-week 54 (full analysis set for the DB-
maintenance phase and OL-maintenance phase)
DB-Maintenance phase# OL-Maintenance phase#
Golimumab SC 100 mg Placebo 100 mg Golimumab SC 100 mg
N 32 31 60
Mayo score at baseline 3.0 (0;8) 3.0 (0;7) 8.0 (4;11)
Change in the Mayo Score from baseline
M-week 30a 0.0 (-5;6) 4.0 (-2;8) 0.0 (-8;2)
M-week 54a -0.5 (-6;6) 5.0 (-3;8) 0.0 (-10;6)
Mucosal healing, n (%)
M-week 30a 19 (59%) 8 (26%) 9 (15%)
M-week 54a 20 (63%) 5 (16%) 9 (15%)
Corticosteroid use at baseline 15.0 (1.0;20.0) 15.0 (4.6;30.0) 7.50 (2.5;20.0)
Change in corticosteroid use
M-week 30a -2.50 (-20.0;0.0) 0.0 (-30.0;0.0) 0.0 (-10.0;0.0)
M-week 54a -1.0 (-20.0; 0.0) 0.0 (-30.0;0.0) 0.0 (-12.0;0.0)
C-reactive protein concentration at baseline (mg/L) 0.36 (0.1;24.0) 0.26 (0.1;22.8) 1.16 (0.1;29.8)
Change in C-reactive protein concentration (mg/L)
M-week 30a 0.08 (-9.7;11.2) 0.25 (-9.7;13.4) -0.065 (-22.8;77.0)
M-week 54a 0.035 (-9.7; 11.2) 0.250 (-9.7;17.2) -0.02 (-22.8;77.0)
Fecal lactoferrin concentration at baseline (lg/g)b 1.20 (-0.9;2.7) 0.78 (-0.5;3.0) 1.89 (-0.5;3.4)
Change in fecal lactoferrin concentration (lg/g)b
M-week 30a 0.00 (-3.2;3.0) 0.79 (-2.0;3.1) 0.05 (-3.1;1.3)
M-week 54a -0.04 (-2.9;3.0) 0.76 (-2.7;3.1) -0.01 (-4.8;1.3)
Fecal calprotectin concentration at baseline (mg/kg)b 1.99 (1.2;2.9) 1.88 (1.2;3.0) 2.52 (1.2;3.0)
Change in fecal calprotectin concentration (mg/kg)b
M-week 30a 0.0 (-1.6;1.3) 0.48 (-1.2;1.7) 0.05 (-1.6;1.1)
M-week 54a 0.0 (-1.6;1.3) 0.54 (-1.7;1.7) 0.06 (-1.8;1.1)
All values expressed as median (range) unless otherwise mentioned
FAS-DB double-blind maintenance phase full analysis set
a Patients who had a missing value for a parameter at any time point had their last available value carried forward to that time point
b Log-transformed values
# Baseline is defined as maintenance M-week 0, DB double-blind, OL open-label, SC subcutaneous injection, SD standard deviation
J Gastroenterol
123
and was the most common markedly abnormal hematology
observation.
Maintenance phase (DB and OL)
During the DB-maintenance phase, the proportion of
patients experiencing C1 TEAE in the golimumab 100 mg
group was 97% (31/32) and in the placebo group, it was
71.0% (22/31). The most frequently ([10%) reported
TEAEs in the golimumab 100 mg group were
nasopharyngitis (53.1%) and injection site erythema
(15.6%). Serious TEAEs were reported in 3.1% (1/32,
Takayasu’s arteritis) of patients in the golimumab 100 mg
group as compared with 12.9% (4/31, colitis ulcerative,
hand fracture, joint dislocation and cerebral infarction) of
patients in the placebo group. Among the randomized
patients, 35.5% (11/31) patients on placebo and 65.6% (21/
32) patients treated with golimumab reported at least one
treatment-emergent infection, with nasopharyngitis as the
most frequently reported infection. Injection site reactions
were reported only by patients receiving golimumab 18.8%
(6/32) with injection site erythema [15.6% (5/32)] being
the most frequent. Reduction in lymphocytes was reported
in 12/30 (40%) patients in the placebo group and 4/32
(12.5%) of patients in the golimumab 100 mg group.
During the OL-maintenance phase, 78.3% (47/60) of the
nonrandomized patients experienced TEAEs. Serious
TEAEs were reported in 6/60 patients; worsening of UC
was observed in 5 patients and infection was observed in 5
patients (Table 3). Of the 60 nonrandomized patients, 26
(43.3%) experienced at least one infection, with
nasopharyngitis 21.7% (13/60) being the most frequently
reported infection. Injection site reactions were reported in
only 3.3% (2/60) of patients. Decreased lymphocytes were
reported in 14/58 (24.1%) non-randomized patients and
was the most common markedly abnormal postbaseline
hematology observation.
Overall, no incidences of active TB or malignancy and
no deaths were reported during this study. No clinically
relevant changes from baseline in the hematology param-
eters and clinical laboratory parameters were observed
during the study..
Discussion
Subcutaneous injection of golimumab, a fully human anti-
TNFa antibody, has demonstrated clinical efficacy in
recent double-blind, randomized placebo-controlled global
studies by effectively achieving and maintaining CR and
remission in patients with moderate to severely active UC
[9, 10]. However, in these global studies, no definitive
conclusions about the effectiveness of golimumab SC as a
maintenance therapy in Japanese patients could be drawn
due to the limited number of patients from this region. The
current study was the first to assess the efficacy and safety
of golimumab SC as both induction and maintenance
therapy particularly in Japanese patients. In the current
study, efficacy and safety of golimumab therapy was
assessed in UC patients who were refractory or intolerant
to 5-ASAs, corticosteroids and/or immunomodulators.
Consistent with the results of the global PURSUIT-M
study, CR was achieved with golimumab therapy in 56.3%
of induction responders through M-week 54 during the DB-
maintenance phase. Furthermore, golimumab treatment
showed 36.9% more efficacy compared with the placebo;
thus, the primary efficacy endpoint was achieved based on
the predetermined criterion for efficacy (CR100–CRP
C8.5%). The safety results indicated that, consistent with
the global studies, golimumab was well-tolerated in this
patient population.
At the end of the induction phase, 43.8% of UC patients
achieved CR to golimumab. These results are generally
consistent with a global induction study wherein a similar
proportion of patients (51.0%) achieved CR with goli-
mumab SC 200 mg at the end of a 6-week induction phase
[9]. The Japanese subpopulation of the PURSUIT-SC
study, however, showed a lower CR of 26.1% during the
induction phase as compared with the CR observed in the
present study (43.8%) [14]. During the DB-maintenance
phase, the observation of CR with golimumab 100 mg in
56.3% of patients in the maintenance phase of this study is
also comparable with the global golimumab SC mainte-
nance study (49.7%) [10].
Results of secondary endpoints including clinical remis-
sion status and mucosal healing at both M-week 30 and
M-week 54 further substantiate the efficacy of golimumab
therapy in this study. Clinical remission observed during the
induction phase was maintained at M-week 30 and M-week
54 in golimumab-treated patients as compared with placebo-
treated patients. A decrease in the Mayo score and partial
Mayo score obtained at baseline of maintenance phase from
I-week 0 were maintained through the end of study. Mucosal
healing was achieved by more than 50% patients at M-week
30 and M-week 54 as compared with placebo, further sup-
porting the efficacy of golimumab 100 mg over placebo.
Mucosal healing determined by the endoscopy subscore of 0
or 1 [15] has emerged as one of the most significant treatment
goals in IBD such as UC and Crohn’s disease, as it assesses
disease activity and helps predict sustained clinical remis-
sion. Thus, with similar CR, clinical remission and mucosal
healing observed in the present study, the current results of
golimumab treatment in the Japanese population are com-
parable with the overall global population.
Currently, infliximab and adalimumab are approved for
the biological therapy of UC in Japan. Golimumab is the
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latest addition to the anti-TNF class of drugs and offers
some advantages over the conventional biological treat-
ments. In addition, golimumab treatment may prove to be
beneficial over the other treatments such as adalimumab in
terms of a longer dosing schedule (4- vs. 2-week) for
maintenance treatment. An important point to consider is
the relatively convenient ease of administration of goli-
mumab SC, as compared with other treatments like
infliximab, which require intravenous administration in
hospital settings [16].
One of the key roles of an ideal UC therapy is to reduce
the need for concomitant corticosteroid therapy and lower
the consequent side effects. Several agents such as aza-
thioprine and 5-ASA have been evaluated for their ability
to discontinue steroid therapy and induce steroid-free
remission [17]. In this study, golimumab reduced the mean
daily corticosteroid dose at both M-week 30 and M-week
54 from baseline and 55.6% patients on golimumab treat-
ment achieved clinical remission and discontinued corti-
costeroid use at M-week 54. Patient-related improvements
in disease status, quality of life and patient preferences as
measured by IBDQ score are gaining impetus and IBDQ
score is now being used as a measure of clinical effec-
tiveness in UC [18]. An increase in the median IBDQ score
was noted at the end of the induction phase and was
maintained through M-week 54. This tendency is consis-
tent with that observed in the PURSUIT-M study [10].
Inflammation is indicated as an underlying cause of UC
and various treatment regimens have been evaluated for
their effects on suppressing these subclinical inflammations
[19]. The inflammatory biomarker CRP and stool
biomarkers with enhanced specificity for intestinal
inflammation such as fecal lactoferrin, and fecal calpro-
tectin [19] were also assessed to estimate the effects of
golimumab in reducing the degree of mucosal inflamma-
tion. In the current study, the initial reduction in these
biomarker levels was observed at the end of the induction
phase and was maintained through M-week 54, suggesting
the positive effects of golimumab SC in controlling
inflammation associated with UC. The incidence of anti-
bodies to golimumab was low through M-week 54, con-
sistent with that observed in the global study [10].
No new safety signals were observed with golimumab
treatment in this UC patient population from Japan. There
were no deaths and no cases of active TB or malignancy
reported during this study. The pattern of TEAEs, serious
TEAEs, infections and injection site reactions during this
study were comparable to the global study [9, 10].
The findings of this study are limited by the fact that it was
not statistically powered to detect a difference between the
golimumab and placebo groups for the end point of mainte-
nance of clinical remission. All between-group comparisons
were descriptive and no formal statistical tests were applied to
detect the differences between the two treatment groups.
Table 3 Summary of treatment-emergent adverse events (full analysis set for the DB-maintenance phase and OL-maintenance phase)
DB-Maintenance phase OL-Maintenance phase
Golimumab SC 100 mg Placebo 100 mg Golimumab SC 100 mg
N 32 31 60
Average duration of follow-up (weeks) 49.0 24.2 21.5
Average exposure (number of administrations) 12.6 6.4 5.5
Number of patients reporting C1 incidence
Any TEAE 31 (96.9%) 22 (71.0%) 47 (78.3%)
Serious TEAE 1 (3.1%) 4 (12.9%) 6 (10.0%)
Reasonably related TEAEs 11 (34.4%) 2 (6.5%) 8 (13.3%)
Infections 21 (65.6%) 11 (35.5%) 26 (43.3%)
Injection site reactions 6 (18.8%) 0 2 (3%)
Erythema 5 (15.6%) 0 1 (1.7%)
Gastrointestinal disorders 5 (15.6%) 5 (16.1%) 18 (30.0%)
Colitis ulcerative 0 2 (6.5%) 6 (10.0%)
Infections and infestations 20 (62.5%) 13 (41.9%) 3 (5%)
Nasopharyngitis 17 (53.1%) 7 (22.6%) 14 (23.3%)
Influenza 4 (12.5%) 1 (3.2%) 3 (5.0%)
Conjunctivitis 1 (3.2%) 1 (3.2%) 1 (1.7%)
Oral herpes 1 (3.1%) 3 (9.7%) 2 (3.3%)
All values expressed as n (%) unless otherwise mentioned
DB double blind, OL open-label, SC subcutaneous injection, SD standard deviation, TEAE treatment-emergent adverse event
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To summarize, the encouraging efficacy and safety
outcomes of the current study and the two global studies
collectively demonstrate the consistent clinical benefit and
positive benefit/risk profile of golimumab treatment. Thus,
golimumab can be an additional valuable treatment option
for moderate to severe UC in patients from Japan.
Acknowledgements The authors thank the study participants without
whom this study would never have been accomplished. The authors
thank Colleen Marano, PhD, Hongyan Zhang and Omoniyi Ade-
dokun, M.S., R.Ph. (from the global Janssen R&D, LLC PURSUIT
team) and Takayuki Ota (Janssen Pharmaceutical K.K.) for their
contributions in this study. The authors also thank Ms. Shweta Pitre,
ISMPP CMPPTM for providing writing assistance, Dr. Madhavi Patil
for editorial assistance (Both SIRO Clinpharm Pvt. Ltd.) and Keni-
chiro Tsutsumi, (Janssen Pharmaceutical K.K.) for providing publi-
cation support for this manuscript.
Funding This study was funded by Janssen Pharmaceutical K.K.,
Tokyo, Japan.
Authors Contributions Asako Senoo, Yoshifumi Ukyo and Toshi-
fumi Hibi were involved in conception and design of the study.
Yoshifumi Ukyo was involved in the data analysis. All authors were
involved in data interpretation, manuscript development and critical
evaluation of this manuscript. All authors approved the final manu-
script for submission, had full access to all the data in this study and
take final responsibility for the decision to submit for publication.
Compliance with ethical standards
Conflict of interest Yuya Imai, Asako Senoo, Kentaro Ohta and
Yoshifumi Ukyo are employees of Janssen Pharmaceutical K.K.,
Japan. Dr. Toshifumi Hibi is a consultant for Janssen Pharmaceutical
K.K., Japan.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet.
2012;380:1606–19.
2. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and
natural history of inflammatory bowel diseases. Gastroenterol-
ogy. 2011;140:1785–94.
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel
disease: incidence, prevalence, and environmental influences.
Gastroenterology. 2004;126:1504–17.
4. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat
Rev Gastroenterol Hepatol. 2015;12:205–17.
5. Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the
epidemiology of inflammatory bowel disease in Asia. Am J
Gastroenterol. 2008;103:3167–82.
6. Hanauer SB, Present DH. The state of the art in the management
of inflammatory bowel disease. Rev Gastroenterol Disord.
2003;3:81–92.
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for
induction and maintenance therapy for ulcerative colitis. N Engl J
Med. 2005;353:2462–76.
8. Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis.
J Clin Pharmacol. 2007;47:930–41.
9. Sandborn WJ, Feagan BG, Marano C. Subcutaneous golimumab
induces clinical response and remission in patients with moder-
ate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–
95 quiz e14-5.
10. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous goli-
mumab maintains clinical response in patients with moderate-to-
severe ulcerative colitis. Gastroenterology. 2014;146(96–109):e1.
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral
5-aminosalicylic acid therapy for mildly to moderately active
ulcerative colitis. N Engl J Med. 1987;317:1625–9.
12. Irvine EJ, Feagan B, Rochon J. Quality of life: a valid and reli-
able measure of therapeutic efficacy in the treatment of inflam-
matory bowel disease. Gastroenterology. 1994;106:287–96.
13. Higgins PDR, Schwartz M, Mapili J, et al. Patient defined
dichotomous end points for remission and clinical improvement
in ulcerative colitis. Gut. 2005;54:782–8.
14. Hibi T, Imai Y, Ota T. Efficacy and safety of golimumab sub-
cutaneous administration in Japanese patients with moderately to
severely active ulcerative colitis (PURSUIT-J). In: Poster pre-
sented at 4th annual meeting of Asian Organization for Crohn’s
& Colitis, Kyoto, Japan. 7–9 July 2016. Poster no. PO-063.
15. Paine ER. Colonoscopic evaluation in ulcerative colitis. Gas-
troenterol Rep (Oxf). 2014;2:161–8.
16. Lo¨wenberg M, de Boer NKH, Hoentjen F. Golimumab for the
treatment of ulcerative colitis. Clin Experimental Gastroenterol-
ogy. 2014;7:53–9.
17. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled
trial of azathioprine and 5-aminosalicylic acid for treatment of
steroid dependent ulcerative colitis. Gut. 2006;55:47–53.
18. Panes J, Su C, Bushmakin AG, et al. Randomized trial of
tofacitinib in active ulcerative colitis: analysis of efficacy based
on patient-reported outcomes. BMC Gastroenterol. 2015;15:14.
19. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal
calprotectin, and stool lactoferrin for detection of endoscopic
activity in symptomatic inflammatory bowel disease patients: a
systematic review and meta-analysis. Am J Gastroenterol.
2015;110:802–19.
J Gastroenterol
123
